Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Capital Expenditures (2016 - 2025)

Coherus Oncology's Capital Expenditures history spans 13 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to $8.4 million; the TTM value through Dec 2025 reached -$470.3 million, down 106.43%, while the annual FY2025 figure was -$470.3 million, 106.43% down from the prior year.
  • Capital Expenditures for Q4 2025 was $8.4 million at Coherus Oncology, up from -$483.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $8.4 million in Q4 2025 and bottomed at -$483.4 million in Q2 2025.
  • The 5-year median for Capital Expenditures is $206500.0 (2021), against an average of -$43.4 million.
  • The largest annual shift saw Capital Expenditures skyrocketed 324.14% in 2022 before it tumbled 123667.76% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $468000.0 in 2021, then crashed by 81.41% to $87000.0 in 2022, then plummeted by 60.92% to $34000.0 in 2023, then crashed by 117747.06% to -$40.0 million in 2024, then soared by 120.94% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Capital Expenditures are $8.4 million (Q4 2025), -$483.4 million (Q2 2025), and $4.7 million (Q1 2025).